← All trials
NCT05583552
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2022
- Primary completion
- Jan 31, 2024
- Completion date
- Jun 30, 2026
- First posted
- Oct 17, 2022
- Last posted
- Oct 17, 2022
- Enrollment
- 46
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- GCP-Service International Ltd. & Co. KGLead sponsor
- Geron CorporationCollaborator
- University of LeipzigCollaborator
- University of LeipzigOverall official - principal investigator
- Australasian Leukaemia and Lymphoma GroupCollaborator
- Groupe Francophone des MyelodysplasiesCollaborator
- University of QueenslandCollaborator
- University of ParisCollaborator
- German Myelodysplastic Syndrome Study GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.